As part of a series of public briefings and policy debates hosted by the Geneva Global Health Hub (G2H2), 15-19 January 2024, ahead of WHO Executive Board 154, the Elizabeth Glaser Pediatric AIDS Foundation and GAP-f have organized a session on advocacy efforts to strengthen high-level political attention and accountability on innovation and access to paediatric medicines.
Despite sustained efforts by Member States, the World Health Organization Secretariat, and other actors, many countries still face challenges in ensuring availability, affordability, and rational use of quality-assured medicines for children. It is of critical importance to continue advocating for innovations and access to quality, safe, efficacious, and affordable medicines for children to achieve better health for all. The 154th session of the WHO Executive Board includes an agenda item on acceleration towards the Sustainable Development Goal targets for maternal health and child mortality.
The objectives of the session are to support coordinated ongoing advocacy efforts to strengthen high-level political attention and accountability on innovation and access to paediatric medicines, in light of existing resolutions and commitments related to access to medicines, and to discuss opportunities to advocate together in light of the WHO EB154 agenda item on acceleration towards the Sustainable Development Goal targets for maternal health and child mortality. The discussion will also inform an advocacy brief on access to better medicines for children developed by the Global Accelerator for Paediatric Formulations, a WHO Network created to respond to the paediatric medicines gap.
Webinar
Time: 13:00-14:30 CET
Speakers include:
- Michelle Childs, Policy Advocacy Director, DNDi
